Esperion Therapeutics (NASDAQ: ESPR) stock is soaring 5.26% in pre-market trading on Monday following the announcement of promising new data from its CLEAR Outcomes study. The results, presented at the American Heart Association (AHA) Scientific Sessions 2025, highlight the value of the company's drug NEXLETOL (bempedoic acid) in reducing major adverse cardiovascular events and venous thromboembolism.

The study revealed that patients receiving bempedoic acid monotherapy experienced a 14% reduction in major adverse cardiovascular events (MACE-4) compared to placebo. This analysis included approximately 8,200 patients who were not on other lipid-lowering therapies. Additionally, an exploratory analysis showed that patients treated with bempedoic acid were 42% less likely to experience venous thromboembolism events compared to those on placebo.

Dr. Luke Laffin, Associate Professor of Medicine at the Cleveland Clinic Lerner College of Medicine and senior author of the CLEAR Outcomes sub-analyses, emphasized the significance of these findings. "The new data demonstrates the efficacy of bempedoic acid alone on reducing CV risk and suggests bempedoic acid may have benefits beyond preventing atherosclerosis by preventing deep venous thrombosis and pulmonary embolism," he stated. These results could potentially expand the therapeutic applications of NEXLETOL, boosting investor confidence in Esperion's future prospects.